Nchi: Singapoo
Lugha: Kiingereza
Chanzo: HSA (Health Sciences Authority)
Medium chain triglycerides; Purified fish oil; Refined olive oil; Soybean oil
FRESENIUS KABI (SINGAPORE) PTE LTD
B05BA02
60g per 1000ml
INJECTION, EMULSION
Medium chain triglycerides 60g per 1000ml; Purified fish oil 30g per 1000ml; Refined olive oil 50g per 1000ml; Soybean oil 60g per 1000ml
INTRAVENOUS
General Sale List
Fresenius Kabi Austria GmbH
ACTIVE
2007-04-12
PACKAGE INSERT _SM0FLIPID 200 MG/ML _ EMULSION FOR INFUSION 1000 ml contain: Soybean oil, refined 60.0 g Medium chain triglycerides 60.0 g Olive oil, refined 50.0 g Fish oil, rich in omega 3 acids 30.0 g Total energy: 8.4 MJ/1(= 2000kcal/l) pH-value: approx. 8 Osmolality: approx. 380 mosm/kg INDICATIONS Supply of energy and essential fatty acids and omega-3 fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated. CONTRAINDICATIONS - Hypersensitivity to fish-, egg- soya, or peanut protein or to any of the active substances or excipients. - Severe hyperlipidemia. - Severe liver insufficiency. - Severe blood coagulation disorders. - Severe renal insufficiency without access to hemofiltration or dialysis. - Acute shock. - General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, decompensated cardiac insufficiency. Unstable conditions (e.g. severe post-traumatic conditions, uncompensated diabetes mellitus, acute myocardial infarction, stroke, embolism, metabolic acidosis and severe sepsis and hypotonic dehydration). SPECIAL WARNINGS AND PRECAUTIONS FOR USE The capacity to eliminate fat is individual and should therefore be monitored according to the routines of the clinician. This is in general done by checking the triglyceride levels. Special caution should be taken in patients with a marked risk for hyperlipidemia (e.g. patients with high lipid dosage, severe sepsis and extremely low birth weight infants). The concentration of triglycerides in serum should in general not exceed 3 mmo1/1 during infusion. An overdose may lead to fat overload syndrome. . This medicinal product contains soya-bean oil, fish oil and egg phospholipids, which may rarely cause allergic reactions. Cross allergic reaction has been observed between soya-bean and peanut. Smoflipid should be given with cau Soma hati kamili
2 Package Insert SMOFlipid 20% Emulsion for Infusion 1000 ml contain: Soya-bean oil, refined 60.0 g Medium-chain triglycerides 60.0 g Olive oil, refined 50.0 g Fish oil, rich in omega-3-acids 30.0 g Total energy: 8.4 MJ/l (= 2000 kcal/l) pH-value: approx. 8 Osmolality: approx. 380 mosm/kg H O Indications Supply of energy and essential fatty acids and omega-3 fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated. Light exposure of solutions for intravenous parenteral nutrition, especially after admixture with trace elements and/ or vitamins, may have adverse effects on clinical outcome in neonates, due to generation of peroxides and other degradation products. When used in neonates and children below 2 years, Smoflipid should be protected from ambient light until administration is completed (see Dosage and administration, Storage and Shelf life and Instruction for use and handling). High levels of lipids in plasma may interfere with some laboratory blood tests, e.g. haemoglobin. The addition of other medicaments or substances to Smoflipid should generally be avoided unless compatibility is known. Interaction Heparin given in clinical doses causes a transient increase in lipoprotein lipase release into the circulation. This may initially result in increased plasma lipolysis, followed by a transient decrease in triglyceride clearance. Soya-bean oil has a natural content of vitamin K .The Contraindications content is however so low in Smoflipid that it is not 1 expected - Hypersensitivity to fish-, egg-, soya or peanut protein or to any of the active substances or excipients. - Severe hyperlipidemia. - Severe liver insufficiency. - Severe blood coagulation disorders. - Severe renal insufficiency without access to hemofiltration or dialysis. - Acute shock. - General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, decompensated cardiac insufficiency. - Unstable conditions (e.g. severe post-traumat Soma hati kamili